Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

A Novel Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivative, N25, Exhibiting Improved Antitumor Activity in both Human U251 and H460 Cells

  • Zhang, Song (Department of Pharmacology, College of Pharmacy, Guangdong Pharmaceutical University) ;
  • Huang, Wei-Bin (Department of Pharmacology, College of Pharmacy, Guangdong Pharmaceutical University) ;
  • Wu, Li (Department of Pharmacology, College of Pharmacy, Guangdong Pharmaceutical University) ;
  • Wang, Lai-You (Department of Pharmacology, College of Pharmacy, Guangdong Pharmaceutical University) ;
  • Ye, Lian-Bao (Department of Pharmacology, College of Pharmacy, Guangdong Pharmaceutical University) ;
  • Feng, Bing-Hong (Department of Pharmacology, College of Pharmacy, Guangdong Pharmaceutical University)
  • Published : 2014.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

$N^1$-(2, 5-dimethoxyphenyl)-$N^8$-hydroxyoctanediamide (N25) is a novel SAHA cap derivative of HDACi, with a patent (No. CN 103159646). This invention is a hydroxamic acid compound with a structural formula of $RNHCO(CH_2)6CONHOH$ (wherein R=2, 5dimethoxyaniline), a pharmaceutically acceptable salt which is soluble. In the present study, we investigated the effects of N25 with regard to drug distribution and molecular docking, and anti-proliferation, apoptosis, cell cycling, and $LD_{50}$. First, we designed a molecular approach for modeling selected SAHA derivatives based on available structural information regarding human HDAC8 in complex with SAHA (PDB code 1T69). N25 was found to be stabilized by direct interaction with the HDAC8. Anti-proliferative activity was observed in human glioma U251, U87, T98G cells and human lung cancer H460, A549, H1299 cells at moderate concentrations ($0.5-30{\mu}M$). Compared with SAHA, N25 displayed an increased antitumor activity in U251 and H460 cells. We further analyzed cell death mechanisms activated by N25 in U251 and H460 cells. N25 significantly increased acetylation of Histone 3 and inhibited HDAC4. On RT-PCR analysis, N25 increased the mRNA levels of p21, however, decreased the levels of p53. These resulted in promotion of apoptosis, inducing G0/G1 arrest in U251 cells and G2/M arrest in H460 cells in a time-dependent and dose-dependent manner. In addition, N25 was able to distribute to brain tissue through the blood-brain barrier of mice ($LD_{50}$: 240.840mg/kg). In conclusion, our findings demonstrate that N25 will provide an invaluable tool to investigate the molecular mechanism with potential chemotherapeutic value in several malignancies, especially human glioma.

Keywords

References

  1. Al-Yacoub N, Fecker LF, Mobs M, et al (2012). Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling. J Invest Dermatol, 132, 2263-74. https://doi.org/10.1038/jid.2012.125
  2. Ammerpohl O, Thormeyer D, Khan Z, et al (2004). HDACi phenylbutyrate increases bystander killing of HSV-tk transfected glioma cells. Biochem Biophys Res Commun, 324, 8-14. https://doi.org/10.1016/j.bbrc.2004.09.016
  3. Darvas K, Rosenberger S, Brenner D, et al (2010). Histone deacetylase inhibitor-induced sensitization to TNFalpha/TRAIL-mediated apoptosis in cervical carcinoma cells is dependent on HPV oncogene expression. Int J Cancer, 127, 1384-92. https://doi.org/10.1002/ijc.25170
  4. Di Fiore A, Maresca A, Supuran CT, De Simone G (2012). Hydroxamate represents a versatile zinc binding group for the development of new carbonic anhydrase inhibitors. Chem Commun (Camb), 48, 8838-40. https://doi.org/10.1039/c2cc34275h
  5. Di Micco S, Chini MG, Terracciano S, et al (2013). Structural basis for the design and synthesis of selective HDAC inhibitors. Bioorg Med Chem, 21, 3795-807. https://doi.org/10.1016/j.bmc.2013.04.036
  6. Di Micco S, Terracciano S, Bruno I, et al (2008). Molecular modeling studies toward the structural optimization of new cyclopeptide-based HDAC inhibitors modeled on the natural product FR235222. Bioorg Med Chem, 16, 8635-42. https://doi.org/10.1016/j.bmc.2008.08.003
  7. Dubois F, Caby S, Oger F, et al (2009). Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol Biochem Parasitol, 168, 7-15. https://doi.org/10.1016/j.molbiopara.2009.06.001
  8. Duo J, Ma Y, Wang G, Han X, Zhang C (2013). Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line. DNA Cell Biol, 32, 156-64. https://doi.org/10.1089/dna.2012.1926
  9. Ellis L, Pan Y, Smyth GK, et al (2008). Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin Cancer Res, 14, 4500-10. https://doi.org/10.1158/1078-0432.CCR-07-4262
  10. Eymin B, Leduc C, Coll JL, Brambilla E, Gazzeri S (2003). p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene, 22, 1822-35. https://doi.org/10.1038/sj.onc.1206303
  11. Feng T, Wang H, Su H, et al (2013). Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2). Bioorg Med Chem, 21, 5339-54. https://doi.org/10.1016/j.bmc.2013.06.009
  12. Finnin MS, Donigian JR, Cohen A, et al (1999). Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 401, 188-93. https://doi.org/10.1038/43710
  13. Hoshino I, Matsubara H (2010). Recent advances in histone deacetylase targeted cancer therapy. Surg Today, 40, 809-15. https://doi.org/10.1007/s00595-010-4300-6
  14. Hoshino I, Matsubara H, Akutsu Y, et al (2007). Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells. Oncol Rep, 18, 585-92.
  15. Hrebackova J, Poljakova J, Eckschlager T, et al (2009). Histone deacetylase inhibitors valproate and trichostatin A are toxic to neuroblastoma cells and modulate cytochrome P450 1A1, 1B1 and 3A4 expression in these cells. Interdiscip Toxicol, 2, 205-10.
  16. Ito N, Sawa H, Nagane M, et al (2001). Inhibitory effects of sodium butyrate on proliferation and invasiveness of human glioma cells. Neurosurgery, 49, 430-6, 436-7.
  17. Kerr JS, Galloway S, Lagrutta A, et al (2010). Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Int J Toxicol, 29, 3-19. https://doi.org/10.1177/1091581809352111
  18. Li XH, Huang ML, Wang SM, Wang Q (2013). Selective inhibition of bicyclic tetrapeptide histone deacetylase inhibitor on HDAC4 and K562 leukemia cells. Asian Pac J Cancer Prev, 14, 7095-100. https://doi.org/10.7314/APJCP.2013.14.12.7095
  19. Li Y, Liu B, Fukudome EY, et al (2011). Identification of citrullinated histone H3 as a potential serum protein biomarker in a lethal model of lipopolysaccharide-induced shock. Surgery, 150, 442-51. https://doi.org/10.1016/j.surg.2011.07.003
  20. Miller CP, Ban K, Dujka ME, et al (2007). NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood, 110, 267-77. https://doi.org/10.1182/blood-2006-03-013128
  21. Nelson HH, Marsit CJ, Christensen BC, et al (2012). Key epigenetic changes associated with lung cancer development: results from dense methylation array profiling. Epigenetics, 7, 559-66. https://doi.org/10.4161/epi.20219
  22. Osada H, Tatematsu Y, Sugito N, Horio Y, Takahashi T (2005). Histone modification in the TGFbetaRII gene promoter and its significance for responsiveness to HDAC inhibitor in lung cancer cell lines. Mol Carcinog, 44, 233-41. https://doi.org/10.1002/mc.20135
  23. Shinji C, Maeda S, Imai K, et al (2006). Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors. Bioorg Med Chem, 14, 7625-51. https://doi.org/10.1016/j.bmc.2006.07.008
  24. Sriraksa R, Limpaiboon T (2013). Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma - cell line findings. Asian Pac J Cancer Prev, 14, 2503-8. https://doi.org/10.7314/APJCP.2013.14.4.2503
  25. Takai N, Kira N, Ishii T, et al (2011). Novel chemotherapy using histone deacetylase inhibitors in cervical cancer. Asian Pac J Cancer Prev, 12, 575-80.
  26. Wanczyk M, Roszczenko K, Marcinkiewicz K, et al (2011). HDACi--going through the mechanisms. Front Biosci (Landmark Ed), 16, 340-59. https://doi.org/10.2741/3691
  27. Xia G, Schneider-Stock R, Diestel A, et al (2008). Helicobacter pylori regulates p21 (WAF1) by histone H4 acetylation. Biochem Biophys Res Commun, 369, 526-31. https://doi.org/10.1016/j.bbrc.2008.02.073
  28. Yoshioka T, Yogosawa S, Yamada T, Kitawaki J, Sakai T (2013). Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS. Gynecol Oncol, 129, 425-32. https://doi.org/10.1016/j.ygyno.2013.02.008

Cited by

  1. Ethanol but not Aqueous Extracts of Tubers of Sauromatum Giganteum(Engl.) Cusimano and Hett Inhibit Cancer Cell Proliferation vol.15, pp.24, 2015, https://doi.org/10.7314/APJCP.2014.15.24.10613
  2. Synthesis, Biological Evaluation, and Computer-Aided Drug Designing of New Derivatives of Hyperactive Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitors vol.86, pp.4, 2015, https://doi.org/10.1111/cbdd.12554